NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Coherus Oncology, Inc. (CHRS) Stock Analysis

Coherus Oncology, Inc. (CHRS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CHRS

$1.42

+$0.05 (+3.65%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CHRS with… →

CHRS Key Statistics

As of Sep 4, 2026
Trading
Open
$1.38
Previous Close
$1.37
Day's Range
1.38–1.44
52-Week Range
1.09–2.62
Volume
304.10K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.94
Valuation
Market Cap
$219.39M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
4.31
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.29
Financials (FY)
Revenue (FY)
$42.17M+59.81%
Net Income (FY)
$168.02M+489.41%
Profit marginThe share of revenue left as profit after all costs and taxes.
−259.41%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
154.50M
1-Year Return
+8.40%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
987.01K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CHRS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+0.00%
2025+2.90%
2024−58.56%
2023−57.95%
2022−50.38%
2021−8.17%
2020−3.47%
2019+98.95%
2018+2.84%
2017−68.74%
2016 (partial year)−6.29%

As of September 4, 2026.

CHRS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$42.17M$168.02M398.4%
2024$26.39M$28.51M108.0%
2023$257.24M−$237.89M−92.5%
2022$211.04M−$291.75M−138.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$42.17M$28.36M−$181.13M$168.02M398.4%
2024$26.39M$17.66M−$199.65M$28.51M108.0%
2023$257.24M$98.25M−$203.20M−$237.89M−92.5%
2022$211.04M$140.96M−$256.88M−$291.75M−138.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CHRS Valuation vs Biotechnology Median

Median of 656 stocks
MetricCHRSBiotechnology medianvs median
P/S ratio4.3115.260.3x the median
Profit margin−259.41%0.00%259.4 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 13 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Coherus Oncology, Inc. (CHRS) at $219.39M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 144 employees.

Over the past 52 weeks the price has ranged from $1.09 to $2.62. The most recent close on file for CHRS is $1.42, dated September 4, 2026. That is +$0.05 (+3.65%) against the previous close. The latest close sits 30.28% above that 52-week low.

Financial Health

In fiscal 2025, Coherus Oncology, Inc. reported revenue of $42.17M. Against the prior fiscal year total of $26.39M, that is a change of +59.81%. The same year closed with net income of $168.02M. That is +489.41% against the prior fiscal year. The reported profit margin is −259.41%. That is 259.4 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −1.29.

Across the 4 fiscal years on file, revenue moves from $211.04M in 2022 to $42.17M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 4.31. On price-to-sales that is 0.3 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned +8.40%. Across 10 years the annualized return works out at −26.49%. The reported beta is 0.94. Annualized volatility over the trailing 10 years is 74.64%.

Growth & Income

No dividend is on file for CHRS.

Across the complete calendar years on file, 2019 returned +98.95% and 2017 returned −68.74%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the price is 0.00%.

Peer Comparison

Coherus Oncology, Inc. (CHRS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Coherus Oncology, Inc. CHRS $219.39M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Coherus Oncology, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Coherus Oncology, Inc.

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.

Visit website →